Immune-related hypophysitis is most frequently associated with the CTLA-4 inhibitor ipilimumab and although hypophysitis has also been reported in patients receiving anti-PD1/PD-L1 therapy, this occurs with a much lower incidence (28). Here, CTLA4 is linked to hypophysitis.